iOncologi Inc, a US-based clinical-stage biopharmaceutical company, announced on Friday that it has acquired TargImmune Therapeutics, a Swiss biotechnology company specialising in novel tumour targeted immunotherapies.
The transaction is claimed to improves iOncologi's capabilities in developing immunotherapies for solid tumours. It aligns with the company's broader strategy to expand its therapeutic pipeline, use next-generation RNA-based immunotherapies, and drive innovation in oncology.
As part of the transaction, iOncologi Inc and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99 percent of TargImmune's shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure is intended to ensures the seamless continuation of TargImmune's research into novel tumour-targeted RNA therapies, while benefiting from iOncologi's expanded resources and strategic vision.
Dr Edgardo Rodriguez-Lebron, iOncologi's recently appointed CEO, said: "This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumours. TargImmune's pioneering approaches perfectly align with our mission to develop transformative cancer therapies. By integrating two incredibly talented and highly experienced drug development teams, we are well-positioned to accelerate innovation and bring novel treatments to patients with limited therapeutic options."
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025